DNAVision

The four new SOLiD machines, which will operate in DNAVision's Brussels facility, will add to the company's existing fleet of two Illumina HiSeq 2000 and one Roche 454 GS FLX.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The new platform will add to the firm's existing next-gen sequencing services on the Illumina HiSeq 2000, Illumina GAIIx, and Roche 454 GS FLX.

DNAVision CEO Jean-Pol Detiffe said this week that the company will use the HiScanSQ for its pharmaceutical and medical research customers' ongoing genome-wide association projects.

The company expects to receive the instrument before the end of June and will install it at its facility in Gosselies, Belgium.

The HiSeq 2000 joins DNAVision's other next-gen sequencing platforms that are used in its genomics services offerings.

People in the News

Klaus Lindpainter is the new VP of R&D and CSO at Strategic Diagnostics; Intrexon appoints Thomas Goralski as senior VP; WARF loses director of licensing Craig Christianson, and more.

New Product Watch

Premium

Randox Laboratories, Ocimum Biosolutions, DNAVision, Illumina

Illumina certified DNAVision to provide genotyping services using Illumina's Infinium platform.

The Belgian companies will offer the microarray analysis platform to biotech and pharma firms.

Pages

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.